Skip to main content
editorial
. 2011 Jul 14;17(26):3075–3081. doi: 10.3748/wjg.v17.i26.3075

Table 2.

Efficacy of combination therapy with systemic acting agents and targeted therapy in hepatocellular carcinoma according to current phase I-II studies

Author Year Phase Investigational drug n RR DS PFS/TTP PFS-6m (%) OS
Sun et al[76] 2007 II Bevacizumab/CapOx 30 11 78 4.5/NR 40 NR
Thomas et al[55] 2009 II Bevacizumab/erlotinib 40 25 42.5 9.0/NR NR 15.7
Hsu et al[77] 2008 II Bevacizumab/capecitabine 45 9 42 4.1/NR NR 10.7
Zhu et al[78] 2006 II Bevacizumab/GemOX 33 20 27 5.3/NR NR 9.6
Berlin et al[79] 2008 II Bortezomib/doxorubicin 39 2.3 25.6 2.4/NR NR 5.7
Asnacios et al[80]1 2008 II Cetuximab/GemOx 45 20 40 4.7/NR NR 9.5
Louafi et al[81]1 2007 II Cetuximab/GemOx 35 24 4.5 NR/NR 40 9.2
Knox et al[82]2 2008 II G3139/doxorubicin 17 0 35 NR/1.8 17.2 5.4
Abou-Alfa et al[83]3 2010 II Sorafenib/doxorubicin 96 4 77 6.9/8.6 2.7 13.7
Richly et al[84] 2009 I Sorafenib/doxorubicin 18 6.3 69 4.04/NR NR NR

1Overlap of patient cohorts cannot be excluded from information provided in the abstracts; 2Trial stopped due to lack of efficacy; 3Trial stopped due to superiority of sorafenib;

4

Calculated from a median duration of disease control rate (combined endpoint for complete and partial response as well as stable disease) of 17.4 wk. CapOx: Capecitabine and oxaliplatin; DS: Disease stabilization (%); GemOx: Gemcitabine and oxaliplatin; NR: Not reported; OS: Overall survival (mo); PFS/TTP: Progression free survival/time to progression (mo); PFS-6m: Progression free survival rate at 6 mo (%); RR: Response rate [complete + partial response (%)].